AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05090605 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS
Study NCT05976035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks
Study NCT05976035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
Study NCT05835427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Extensor Stretch
Description: Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
Study NCT05835427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Extensor Stretch
Description: Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
Study NCT06217744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Intervention
Description: Participants will receive 6 psychoeducational modules design to increase mental health literacy: Module 1: The Stigma of Mental Illness, Module 2: Understanding Mental Health and Mental Illness, Module 3: Information on Specific Mental Illnesses, Module 4: Experiences of Mental Illness, Module 5: Seeking Help and Finding Support, Module 6: The Importance of Positive Mental Health.
Study NCT06217744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended Intervention
Description: Participants will receive the same materials as the Automated Intervention, as well as the possibility to attend psychoeducational sessions held by licensed psychologists.
Study NCT06521112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral care with a solution containing 0.2% chlorhexidine gluconate a frequency determined according to the results of the Intensive Care Oral Care Frequency Rating Scale.
Description: Every day for 10 days, Frequency determined according to Intensive Care Oral Care Frequency Rating Scale, Oral care was applied for 2 minutes a solution containing 0.2% chlorhexidine gluconate.
Study NCT06073756 — intervention group
Intervention type: RADIATION
Intervention: Echocardiogram
Description: Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
Study NCT05476640 — intervention group
Intervention type: GENETIC
Intervention: NGS
Description: In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 1
Description: 6 participants will be assigned to receive active treatment
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 2
Description: 6 participants will be assigned to receive active treatment
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 3
Description: 6 participants will be assigned to receive active treatment
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 4
Description: 6 participants will be assigned to receive active treatment
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 1
Description: 2 participants will be assigned to receive placebo
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 2
Description: 2 participants will be assigned to receive placebo
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 3
Description: 2 participants will be assigned to receive placebo
Study NCT06133478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 4
Description: 2 participants will be assigned to receive placebo
Study NCT05470855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
Study NCT06056362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-LM3
Description: 40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
Study NCT06056362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
Study NCT06056362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-LM3
Description: 40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
Study NCT06056362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3
Description: All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
Study NCT05397340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: active DBS with optimal stimulating parameters
Study NCT05397340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: active DBS with optimal stimulating parameters
Study NCT06287086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRL-101 autologous hematopoietic stem and progenitor cells injection
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
Study NCT06547671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Employment of a confort room to help in anxiety and agitation moments.
Description: Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.
Study NCT06258733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay-led FL workshops
Description: Groups of women recruited by trained lay-leaders will receive an 8-session lay-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the lay workshop facilitator. Lay-leaders will receive an incentive to collect surveys from workshop participants. A member of the research staff will be present at the time of the survey collection to ensure data are collected according to protocol. Monthly phone calls with lay-leaders will take place to ensure implementation in the community, including problem solving and help maintaining motivation. To help ensure implementation in the lay-led arm, lay leaders will be required to complete one workshop in the community before receiving a graduation certificate.
Study NCT06258733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert-led workshops
Description: Matching groups of women recruited by research staff will receive the same 8-session expert-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the expert workshop facilitator.
Study NCT05975632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Self testing Potassium device
Description: Calibration Phase (1 visit) (Hemodialysis patients and subjects not on dialysis) Each patient will have one venous blood collection. Among them, one 30 patients one capillary sample is collected. In this phase, the HCP is the user of the device.~Comparison Phase~For subject not on dialysis (total 2 visits):~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test~For Hemodialysis patients (total 1 visit) :~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test
Study NCT04129125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoom Reperfusion System
Description: Thrombectomy
Study NCT06408597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Infusion
Description: Nitroglycerin prepared using a vial (50 mg nitroglycerin) transferred into a 500 ml glass bottle of sodium chloride injection (0.9%), this yields a concentration of 100 mcg/ml.~Patients in the nitroglycerin group will receive nitroglycerin infusion at a rate of 0.25 mic/kg/min all through the surgery, to be discontinued in the PACU.
Study NCT06408597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mannitol Infusion
Description: Mannitol will be prepared through diluting 100 ml of the 20% solution with 180 ml of sodium chloride injection (0.9%).~Patients in the mannitol group will receive an infusion bolus of mannitol 20% 0.5gm/kg added to the standard fluid chart via centeral line.~Mannitol intake will be started directly after induction of anaesthesia and before intra-peritoneal gas insufflation, as an infusion over 15 minutes.
Study NCT06408597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Regimen
Description: Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status.
Study NCT06408597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid Regimen
Description: Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status.
Study NCT04699825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular and immunological changes
Description: performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample
Study NCT04699825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular and immunological changes
Description: performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample
Study NCT04400981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
Study NCT04400981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction.
Study NCT04400981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard medical therapy
Description: Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction.
Study NCT06295497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lung-SIGHT
Description: * The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up.
Study NCT06365450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participants will receive hybrid educational intervention on breast and cervical cancer
Study NCT05998330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiverPAL
Description: The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
Study NCT04170101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep NMB
Description: 0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC \< 3
Study NCT05573100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU06-1004
Description: CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
Study NCT06486727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Redtouch
Description: 675-nm laser
Study NCT05254717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counselling
Description: intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
Study NCT05425225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level LASER therapy
Description: Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds. Two sessions will be given per week for total of 6 weeks.(20)
Study NCT05425225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Hot pack for 15 to 20 minutes followed by 10 repetitions of sustained stretching (10 seconds hold), for 3 days a week for 6 week
Study NCT06372106 — intervention group
Intervention type: DEVICE
Intervention: SaO2 Sampling
Description: CO-Oximetry analysis of arterial blood samples
Study NCT05393622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION
Description: Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
Study NCT05771025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatectomy
Description: Patients in the hepatectomy group receive liver resection.
Study NCT05199857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE BEAT Group Wellness Education program - phase 1
Description: Participants will be assigned into a small group with 3-6 other participants and will participate in a weekly, 45-50 minute intervention session for 5 weeks, delivered by a licensed clinical psychologist or limited licensed clinical psychology fellow using University of Michigan (UM) Zoom. Each session will focus on a particular skill related to wellness and resiliency. There will also be a short battery of questionnaires to complete.
Study NCT05199857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART Club Home Exercise program - phase 2
Description: This is an individualized home exercise program adapted from the exercise programs used in traditional, hospital-based cardiac rehabilitation. A complete cardiopulmonary exercise test (CPET) may be completed if needed for a baseline and one will be done at the last visit. The exercise physiology team will discuss participants exercise goals, interests, and available resources to help develop the exercise plan for the research study. Once the program is designed, participants will complete the exercise activities in the plan. Over time, participants will advance through various stages in the program and then will be gradually introduced to the principles of exercise rehabilitation and more intense physical exercise. Participants will be asked to wear a wearable activity tracker and have scheduled video check-ins with the exercise physiology team. Throughout the program participants will complete a short battery of surveys.
Study NCT05605288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Coronary angiography +/- percutaneous coronary intervention
Study NCT05605288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Coronary angiography +/- percutaneous coronary intervention
Study NCT05514171 — intervention group
Intervention type: PROCEDURE
Intervention: Neoadyuvant therapy
Description: Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
Study NCT04170101 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: moderate NMB
Description: 0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
Study NCT04773730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior transversus abdominus plane block
Description: Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
Study NCT05144048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient setting
Description: These women stay at the maternity unit
Study NCT05144048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient setting
Description: These women leave the maternity unit
Study NCT04773730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block type 2
Description: Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
Study NCT05667207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care microscopy and dipstick guided management
Description: GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~1. If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~2. If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices.
Study NCT05507502 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination administration
Description: There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.